

Nanologica Q4 2024 - Stepping into the next phase

Redeye updates its view on Nanologica following the year-end report and recent news flow. While maintaining a positive stance on the case, we lower our near-term sales projections and slightly trim our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Nanologica Q4 2024 - Stepping into the next phase